ArticleBMC biotechnology2026
Identification of novel therapeutic targets for ovarian hypofunction through hormonal pathway regulation.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian hypofunction (OH) is a multifactorial endocrine disorder characterized by impaired folliculogenesis, hypoestrogenism, and subfertility, affecting an estimated 10–12% of reproductive-aged women worldwide and up to 1% of women under 40 years of age. Current interventions, including hormone replacement therapy (HRT), gonadotropin stimulation, and assisted reproductive technologies (ART), remain largely symptomatic, carry safety concerns, and fail to restore intrinsic ovarian activity. To address this unmet need, we employed an integrative computational strategy combining systems-level biological insights with immunoinformatics approaches to identify and evaluate a multi-epitope peptide candidate targeting the follicle-stimulating hormone receptor (FSHR). Seven FSHR-derived peptides with high predicted immunogenic potential were identified, validated for non-allergenicity and non-toxicity, and fused with flexible linkers into a 62-amino-acid construct. Physicochemical analysis indicated stability (instability index 38.80), thermostability (aliphatic index 89.68), hydrophilicity (GRAVY −0.365), and favorable solubility (Protein-Sol 0.584 compared with an E. coli average of 0.45). Codon optimization improved the codon adaptation index from 0.64 to 0.90 and reduced GC content from 63.98% to 53.23%, suggesting high expression potential in E. coli. Molecular docking with TLR2 yielded a favorable docking score (−296), supported by extensive hydrogen bonding and hydrophobic interactions. Long-timescale molecular dynamics simulations (500 ns) supported structural stability, with RMSD plateauing at approximately 0.3 nm, a compact radius of gyration (2.52–2.55 nm), and a persistent hydrogen-bond network (1250–1400 bonds). In silico immune simulations suggested balanced humoral and cellular immune responses, characterized by early IgM production, class switching to IgG, IL-2–associated T-cell expansion, and immune memory formation. Overall, this computational study identifies a structurally stable and immunologically promising peptide candidate for ovarian hypofunction, providing a rational basis for future experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.